Does the media refer more to SRPT or EPRX?

In the previous week, Sarepta Therapeutics had 5 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 16 mentions for Sarepta Therapeutics and 11 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.89 beat Sarepta Therapeutics' score of 0.72 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, TRAX or EPRX?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A

Is TRAX or EPRX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Eupraxia Pharmaceuticals N/A -70.45% -46.53%

Does the media favor EPRX or ANAB?

In the previous week, Eupraxia Pharmaceuticals had 8 more articles in the media than AnaptysBio. MarketBeat recorded 11 mentions for Eupraxia Pharmaceuticals and 3 mentions for AnaptysBio. Eupraxia Pharmaceuticals' average media sentiment score of 0.89 beat AnaptysBio's score of 0.63 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, EPRX or AAPG?

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A Ascentage Pharma Group International $82.10M 21.83 -$177.71M N/A N/A

Is EPRX or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -70.45% -46.53% Ascentage Pharma Group International N/A N/A N/A

Eupraxia Pharmaceuticals (EPRX) Competitors

$6.60 +0.12 (+1.82%)

As of 09:45 AM Eastern

Compare

EPRX vs. SRPT, RXRX, TRAX, ANAB, and AAPG

Should you buy Eupraxia Pharmaceuticals stock or one of its competitors? Eupraxia Pharmaceuticals's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Recursion Pharmaceuticals (RXRX), First Tracks Biotherapeutics (TRAX), AnaptysBio (ANAB), and Ascentage Pharma Group International (AAPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eupraxia Pharmaceuticals compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

In the previous week, Sarepta Therapeutics had 5 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 16 mentions for Sarepta Therapeutics and 11 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.89 beat Sarepta Therapeutics' score of 0.72 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$1.97B	0.98	-$713.41M	-$2.90	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Eupraxia Pharmaceuticals	N/A	-70.45%	-46.53%

Sarepta Therapeutics presently has a consensus price target of $25.06, indicating a potential upside of 36.87%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 172.81%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Sarepta Therapeutics and Eupraxia Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Recursion Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 14 mentions for Recursion Pharmaceuticals and 11 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.89 beat Recursion Pharmaceuticals' score of 0.47 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eupraxia Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Recursion Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	23.38	-$644.76M	-$1.04	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Recursion Pharmaceuticals presently has a consensus price target of $8.10, suggesting a potential upside of 145.83%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 172.81%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Eupraxia Pharmaceuticals	N/A	-70.45%	-46.53%

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Recursion Pharmaceuticals and Eupraxia Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to First Tracks Biotherapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

In the previous week, Eupraxia Pharmaceuticals had 4 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 11 mentions for Eupraxia Pharmaceuticals and 7 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.93 beat Eupraxia Pharmaceuticals' score of 0.89 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

First Tracks Biotherapeutics currently has a consensus target price of $60.50, indicating a potential upside of 30.56%. Eupraxia Pharmaceuticals has a consensus target price of $18.00, indicating a potential upside of 172.81%. Given Eupraxia Pharmaceuticals' higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

First Tracks Biotherapeutics' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Eupraxia Pharmaceuticals	N/A	-70.45%	-46.53%

Summary

Eupraxia Pharmaceuticals beats First Tracks Biotherapeutics on 5 of the 9 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

In the previous week, Eupraxia Pharmaceuticals had 8 more articles in the media than AnaptysBio. MarketBeat recorded 11 mentions for Eupraxia Pharmaceuticals and 3 mentions for AnaptysBio. Eupraxia Pharmaceuticals' average media sentiment score of 0.89 beat AnaptysBio's score of 0.63 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has higher revenue and earnings than Eupraxia Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
AnaptysBio	$234.60M	7.23	-$13.23M	-$1.08	N/A

Eupraxia Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-70.45%	-46.53%
AnaptysBio	-11.53%	N/A	-7.75%

Eupraxia Pharmaceuticals presently has a consensus target price of $18.00, suggesting a potential upside of 172.81%. AnaptysBio has a consensus target price of $82.00, suggesting a potential upside of 43.15%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eupraxia Pharmaceuticals is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Eupraxia Pharmaceuticals beats AnaptysBio on 9 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Ascentage Pharma Group International?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Eupraxia Pharmaceuticals currently has a consensus price target of $18.00, indicating a potential upside of 172.81%. Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 141.88%. Given Eupraxia Pharmaceuticals' higher possible upside, equities research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Ascentage Pharma Group International	$82.10M	21.83	-$177.71M	N/A	N/A

Ascentage Pharma Group International's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-70.45%	-46.53%
Ascentage Pharma Group International	N/A	N/A	N/A

Eupraxia Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

In the previous week, Eupraxia Pharmaceuticals had 5 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 11 mentions for Eupraxia Pharmaceuticals and 6 mentions for Ascentage Pharma Group International. Eupraxia Pharmaceuticals' average media sentiment score of 0.89 beat Ascentage Pharma Group International's score of 0.24 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Eupraxia Pharmaceuticals and Ascentage Pharma Group International tied by winning 5 of the 10 factors compared between the two stocks.

Get Eupraxia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EPRX vs. The Competition

Export

Metric	Eupraxia Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$431.08M	$3.74B	$7.08B	$12.88B
Dividend Yield	N/A	3.76%	2.58%	10.74%
P/E Ratio	-6.50	10.36	268.59	25.09
Price / Sales	N/A	1,272.87	652.01	108.45
Price / Cash	N/A	102.94	70.59	50.58
Price / Book	4.68	17.81	13.12	6.23
Net Income	-$38.58M	-$13.23M	$3.45B	$347.40M
7 Day Performance	-0.93%	2.97%	1.82%	1.35%
1 Month Performance	2.61%	1.40%	0.91%	0.51%
1 Year Performance	21.06%	55.33%	67.68%	18.99%

Eupraxia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EPRX Eupraxia Pharmaceuticals	2.4179 of 5 stars	$6.60 +1.8%	$18.00 +172.8%	+20.5%	$431.08M	N/A	N/A	29	Earnings Report Gap Up
SRPT Sarepta Therapeutics	3.5508 of 5 stars	$16.78 +5.3%	$25.06 +49.3%	-2.2%	$1.68B	$1.97B	N/A	1,372
RXRX Recursion Pharmaceuticals	1.8294 of 5 stars	$3.18 +0.3%	$8.10 +154.7%	-39.2%	$1.68B	$74.68M	N/A	400	Options Volume
TRAX First Tracks Biotherapeutics	2.8032 of 5 stars	$45.31 -3.5%	$47.88 +5.7%	N/A	$1.64B	N/A	N/A	N/A	News Coverage Earnings Report Analyst Forecast
ANAB AnaptysBio	2.4484 of 5 stars	$54.77 -0.4%	$82.00 +49.7%	+183.3%	$1.63B	$234.60M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EPRX) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. SRPT, RXRX, TRAX, ANAB, and AAPG

How does Eupraxia Pharmaceuticals compare to Sarepta Therapeutics?

Summary

How does Eupraxia Pharmaceuticals compare to Recursion Pharmaceuticals?

Summary

How does Eupraxia Pharmaceuticals compare to First Tracks Biotherapeutics?

Summary

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Summary

How does Eupraxia Pharmaceuticals compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. SRPT, RXRX, TRAX, ANAB, and AAPG

How does Eupraxia Pharmaceuticals compare to Sarepta Therapeutics?

Does the media refer more to SRPT or EPRX?

Which has more volatility and risk, SRPT or EPRX?

Do insiders and institutionals believe in SRPT or EPRX?

Which has better earnings & valuation, SRPT or EPRX?

Is SRPT or EPRX more profitable?

Do analysts prefer SRPT or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Recursion Pharmaceuticals?

Which has more volatility and risk, RXRX or EPRX?

Does the media refer more to RXRX or EPRX?

Which has higher valuation & earnings, RXRX or EPRX?

Do analysts rate RXRX or EPRX?

Is RXRX or EPRX more profitable?

Do insiders & institutionals have more ownership in RXRX or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to First Tracks Biotherapeutics?

Which has better valuation and earnings, TRAX or EPRX?

Does the media favor TRAX or EPRX?

Do analysts prefer TRAX or EPRX?

Is TRAX or EPRX more profitable?

Summary

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Does the media favor EPRX or ANAB?

Which has preferable valuation & earnings, EPRX or ANAB?

Which has more volatility and risk, EPRX or ANAB?

Is EPRX or ANAB more profitable?

Do analysts recommend EPRX or ANAB?

Summary

How does Eupraxia Pharmaceuticals compare to Ascentage Pharma Group International?

Do analysts rate EPRX or AAPG?

Which has better earnings & valuation, EPRX or AAPG?

Is EPRX or AAPG more profitable?

Which has more volatility and risk, EPRX or AAPG?

Does the media favor EPRX or AAPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools